almotriptan has been researched along with dihydroergotamine in 4 studies
| Studies (almotriptan) | Trials (almotriptan) | Recent Studies (post-2010) (almotriptan) | Studies (dihydroergotamine) | Trials (dihydroergotamine) | Recent Studies (post-2010) (dihydroergotamine) |
|---|---|---|---|---|---|
| 188 | 59 | 42 | 1,450 | 241 | 116 |
| Protein | Taxonomy | almotriptan (IC50) | dihydroergotamine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.09 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.9996 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.001 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0089 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0039 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.395 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.029 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.008 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.09 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0053 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0068 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0032 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Csiba, L; Ficzere, A | 1 |
| Autret-Leca, E; Beau-Salinas, F; Bensouda-Grimaldi, L; Cissoko, H; Jonville-Béra, AP | 1 |
2 review(s) available for almotriptan and dihydroergotamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Treatment of migraine in patients with hypertension and ischemic heart disease].
Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Contraindications; Dihydroergotamine; Dopamine Agonists; Ergotamine; Humans; Hypertension; Indoles; Migraine Disorders; Myocardial Ischemia; Oxazolidinones; Retrospective Studies; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 2002 |
2 other study(ies) available for almotriptan and dihydroergotamine
| Article | Year |
|---|---|
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Risk; Substance-Related Disorders; Sumatriptan; Tryptamines | 2010 |